Last week, Roivant Sciences Ltd. (NASDAQ: ROIV) was one of the best performers as its share prices jumped by 19.4 percent, hitting a new all-time high. Investors were encouraged by results from pipeline projects, with one already seeking NDA approval. The stock reached $25.95 before closing at $25.82.

Roivant’s unit, Priovant, reported strong results from a clinical trial of Brepocitinib for cutaneous sarcoidosis, showing a 22.3 percent improvement in disease activity score compared to a 0.7 percent improvement in the placebo group. An NDA for dermatomyositis treatment has been submitted, with a third trial for non-infectious uveitis expected in late 2026.

Roivant Sciences Ltd. (NASDAQ: ROIV) is also conducting clinical trials for therapy candidates targeting difficult-to-treat conditions like rheumatoid arthritis, Graves’ disease, and more. However, the company reported a net loss of $265.89 million in Q3, a significant swing from the previous year’s net income of $169 million.

Despite the potential of ROIV as an investment, some AI stocks may offer higher returns with lower risk. For those seeking a cheap AI stock with potential benefits from tariffs and onshoring, check out the free report on the best short-term AI stock. Explore more investment opportunities in the 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Read more at Yahoo Finance: Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress